Recent news on Pramlintide Acetate

Amylin Pharmaceuticals to Present at Bank of America Healthcare ...  -  25 May 2007
PharmaLive.com (press release),Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)

Amylin Pharmaceuticals Reports First Quarter Financial Results  -  Apr 16, 2007
PR-Inside.com (Pressemitteilung),Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)

Amylin Pharmaceuticals Reports First Quarter Financial Results  -  Apr 16, 2007
PharmaLive.com (press release),...for the first quarter include $146.5 million for BYETTA(R) (exenatide) injection and $15.5 million for SYMLIN(R) (pramlintide acetate) injection.

$2.5 MILLION AWARDED TO HIGH TECHNOLOGY COMPANIES Third Frontier ...  -  Mar 28, 2007
ODOD (press release),Amylin has developed and gained approval for two first-in-class medicines to treat diabetes, BYETTA® (exenatide) injection and SYMLIN® (pramlintide acetate)

Amylin Pharmaceuticals to Present at Lehman Brothers Global ...  -  Mar 14, 2007
PharmaLive.com (press release),Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)

Amylin Pharmaceuticals Reports 2006 Financial Results  -  Feb 1, 2007
Drug Newswire (press release),Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)

Amylin Pharmaceuticals Reports 2006 Financial Results  -  Jan 30, 2007
Yahoo! News (press release)Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide)

Amylin Pharmaceuticals Reports 2006 Financial Results  -  Jan 30, 2007
Earthtimes.org...for the quarter include sales of $137.0 million for BYETTA(R) (exenatide) injection and $13.6 million for SYMLIN(R) (pramlintide acetate) injection.

Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference  -  Jan 3, 2007
PharmaLive.com (press release),Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)

Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference  -  Jan 2, 2007
Yahoo! News (press release)Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide)

FDA Approves BYETTA(R) (exenatide) Injection for Expanded ...  -  Dec 22, 2006
Yahoo! News (press release)Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide ...

FDA Approves BYETTA(R) (exenatide) Injection for Expanded ...  -  Dec 22, 2006
PR Newswire (press release),Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide ...

Amylin Pharmaceuticals to Present at BIOCOM Investor Conference ...  09 Nov 2006
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide ... -Yahoo! News (press release) Amylin Pharmaceuticals to Present at UBS Warburg Global Life ...  Sep 22, 2006
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide ... -PR Newswire

SYMLIN Improved Diabetes Control in Patients With Type 2 Diabetes ...  Sep 8, 2006
Today announced positive results from a 16-week study evaluating the safety and efficacy of adding SYMLIN(R) (pramlintide acetate) to an established regimen of ... -PipelineReview.com

SYMLIN Improved Diabetes Control In Patients With Type 2 Diabetes ...  Sep 8, 2006
...(Nasdaq: AMLN) today announced positive results from a 16-week study evaluating the safety and efficacy of adding SYMLIN(R) (pramlintide acetate) to an ... -Medical News Today

Amylin Pharmaceuticals to Present at Nordea Novel Anti-Diabetics ...  Sep 15, 2006
Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide ... -Yahoo! News

NutraCea to Present at Roth Capital Growth Conference and ...  Sep 11, 2006
...(Nasdaq: AMLN) recently announced positive results from a 16-week study evaluating the safety and efficacy of adding SYMLIN® (pramlintide acetate) to an ... -Financial News USA

Amylin Pharma Says SYMLIN Improved Diabetes Control In Patients On ...  Sep 7, 2006
...charts | news | PowerRating) announced positive results from a 16-week study evaluating the safety and efficacy of adding SYMLIN® (pramlintide acetate) to an ... -Trading Markets

Amylin Pharmaceuticals to Present at Piper Jaffray Healthcare ...  -  12 Dec 2006
Genetic Engineering News (press release),Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)

Amylin Pharmaceuticals to Present at Piper Jaffray Healthcare ...  -  Nov 24, 2006
Yahoo! News (press release)Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide)

Amylin Pharmaceuticals, Inc. Announces Conversion of All ...  Aug 24, 2006
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide ... -American Digital Networks

Amylin's Amazing Run Still Has Steam  Aug 2, 2006
The US Food and Drug Administration approved Byetta (exenatide) and Symlin (pramlintide acetate) in the spring of 2005, and both injectable drugs are beginning ... -Forbes

Amylin Pharmaceuticals Announces BYETTA Revenue  Jul 21, 2006
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide ... -Yahoo! News



Amylin Pharmaceuticals Reports First Quarter Financial Results  Apr 26, 2006
...of $75.9 million for the first quarter include $68.3 million for BYETTA(R) (exenatide) injection and $7.6 million for SYMLIN(R) (pramlintide acetate) injection ... - PR Newswire





Research and Markets: Amylin's Pramlintide Acetate (Symlin) ...  Mar 27, 2006
Amylin's pramlintide acetate (Symlin) recently received approval as an adjunct therapy in combination with insulin for patients with type 1 diabetes. ... - International News Service

Once-Weekly Exenatide LAR Clinical Study in Type 2 Diabetes ...  Mar 24, 2006
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(TM) (exenatide ... - Finanzen.net



Drug firm welcomed to West Chester  Feb 6, 2006
Amylin has developed and gained approval for two first-in-class medicines for diabetes: Symlin (pramlintide acetate) injection and Byetta (exenatide) injection ... - Cincinnati Business Courier,

Research and Markets: Sanofi-Aventis Recently Filed for Approval ...  Feb 1, 2006
Amylin's pramlintide acetate (Symlin) recently received approval as an adjunct therapy in combination with insulin for patients with type 1 diabetes. ... - International News Service,

Amylin Pharmaceuticals Reports 2005 Financial Results  09 Feb 2006
...$56.2 million for the quarter include sales of $49.7 million for BYETTA(R) (exenatide) injection and $6.5 million for SYMLIN(R) (pramlintide acetate) injection ... - MSN Money

Research and Markets: Sanofi-Aventis Recently Filed for Approval ...  Feb 1, 2006
Amylin's pramlintide acetate (Symlin) recently received approval as an adjunct therapy in combination with insulin for patients with type 1 diabetes. ... - International News Service

Amylin Pharmaceuticals Added to the NASDAQ-100 Index  Jan 9, 2006
Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide ... - Yahoo! News

Biotechnology Industry Ends 2005 with Breakthrough Product ...  Jan 18, 2006
Both diabetes drugs, Byetta is a first-in-class incretin mimetics while Symlin is a pramlintide acetate used in conjunction with insulin to treat Type I and II ... - Yahoo! News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional